BNP Paribas Asset Management’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
SCM
VPM
VCM
S
BNP Paribas Asset Management's NVAX Position: Q1 2026 in Review
BNP Paribas Asset Management increased its Novavax (NVAX) stake by 3,731% in Q1 2026, buying an estimated $551K and bringing the position to 62,453 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.
BNP Paribas Asset Management first reported a position in NVAX in Q4 2013 and has held it in 16 quarters since. The position peaked at $22.5M in Q4 2014. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- BNP Paribas Asset Management held 62,453 shares of Novavax worth $508K as of Q1 2026.
- BNP Paribas Asset Management bought 60,823 Novavax shares in Q1 2026, an estimated $551K.
- Novavax made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1249 holding.
- BNP Paribas Asset Management first reported a position in Novavax in Q4 2013 and has held it in 16 quarters since.
- BNP Paribas Asset Management's Novavax position peaked at $22.5M in Q4 2014.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.